Calibreye (glaucoma implant)

History

2025: Product Announcement

In mid-August 2025, California-based US-based Myra Vision announced the launch of a Calibreye eye implant designed to treat glaucoma without surgery. The new system allows personalized therapy, minimizing complications.

Glaucoma is a group of eye diseases characterized by a constant or periodic increase in intraocular pressure above a level acceptable to humans. The consequences of the disease are a decrease in visual acuity and atrophy of the optic nerve. This rapidly progressive disease can lead to irreversible blindness. According to the World Health Organization (WHO), it is glaucoma that is one of the main causes of visual impairment and blindness worldwide.

𝓲

Фото: Freepik

The Calibreye system after implantation allows specialists to regulate the flow of intraocular fluid in glaucoma patients according to their individual needs. The novelty is an alternative to special shunts for creating the drainage system of the eye, as well as trabeculectomy - an invasive surgical procedure that aims to reduce intraocular pressure by removing part of the trabecular network and adjacent structures of the eye. Calibreye provides customizable outflow based on an individual's current treatment needs. The product design uses a flexible and stable polymer with minimal biodegradation.

Each glaucoma patient is unique and surgical treatment options must adapt to the individual needs of the individual. Traditional treatments such as trabeculectomies and tubular shunts, while effective, can increase the risk of complications. That is why we have developed the Calibreye system, says Myra Vision.[1]

Notes